EMEA (Europe, Middle East and Africa) Celiac Disease Drug Market Report 2018

SKU ID : QYR- 11540074

Publishing Date : 01-May-2018

No. of pages : 111

PRICE
4000
8000


  • In this report, the EMEA Celiac Disease Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

    Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Celiac Disease Drug for these regions, from 2013 to 2025 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

    EMEA Celiac Disease Drug market competition by top manufacturers/players, with Celiac Disease Drug sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    F. Hoffmann-La Roche
    Johnson & Johnson
    Merck
    Pfizer
    ADMA Biologics
    Amgen
    Anthera Pharmaceuticals
    Bayer
    Biogen
    BioLineRx
    Biotest
    Bristol-Myers Squibb
    Celgene
    Takeda Pharmaceutical
    Novartis
    LFB Group
    Kedrion Biopharma

    On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Distension
    Diarrhea
    Anorexia
    Others

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    First line of treatment
    Second line of treatment